What does pitolisants — license agreement upfront fee paid mean?

This represents the total initial consideration paid at the inception of a licensing agreement to obtain rights to a pharmaceutical product or technology. It reflects the immediate cash outlay required to initiate the partnership and secure the asset for the company's portfolio. This metric is a key component of the total cost of acquisition for external innovation.

Harmony Biosciences Holdings, Inc. HRMY Pitolisants — License Agreement Upfront Fee Paid

Similar metrics at other companies

PRAXLicense — Upfront payment

$0—

OPKTransfer Of Intellectual Property And Other — Upfront Payment

$1.75M—

EYPTProduct Rights Agreement — Upfront Cash Payment

$75M0.0%

RLAYPeriodic Change In Costs To Obtain License Agreement Within Current Liabilities

$0+100%

LXRXLicense — Proceeds from collaborators

$10M—

BFLYPayments on Technology License Commitment

$672.75K+105%

Other financials

Income statement

See full

Revenue$215.4M+16.6%

Gross profit$170.9M+11.9%

Operating income$37.3M-33.7%

Net income$32.5M-28.7%

EPS (diluted)$0.55-29.5%

Balance sheet

See full

Cash & equivalents$589.4M+20.5%

Total debt$164.6M-7.2%

Total equity$910.3M+26.3%

Total assets$1.3B+20.5%

Cash flow

See full

Operating cash flow$27.8M-18.3%

CapEx$107.0K-79.1%

Free cash flow$126.0M+67.9%

Valuation

See full

Market cap$1.99B+8.9%

Enterprise value$1.57B+3.3%

P/E13.7×+1.7×

P/S2.2×-0.2×

Profitability

See full

Gross margin76.5%-1.8pp

Operating margin21.1%-5.1pp

Net margin16.2%-4.3pp

FCF margin40.1%+9.5pp

Returns & leverage

See full

Return on equity17.9%-6.9pp

Debt / equity0.2×-0.1×

Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept hrmy:LicenseAgreementUpfrontFeePaid.

The official record: Harmony Biosciences Holdings, Inc.’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s pitolisants — license agreement upfront fee paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s pitolisants — license agreement upfront fee paid?: Harmony Biosciences Holdings, Inc. (HRMY) reported pitolisants — license agreement upfront fee paid of $15M in Q1 2026.
What does pitolisants — license agreement upfront fee paid mean?: This represents the total initial consideration paid at the inception of a licensing agreement to obtain rights to a pharmaceutical product or technology. It reflects the immediate cash outlay required to initiate the partnership and secure the asset for the company's portfolio. This metric is a key component of the total cost of acquisition for external innovation.